Boston Scientific Co. (NYSE:BSX) CEO Michael F. Mahoney sold 201,042 shares of the business’s stock in a transaction that occurred on Monday, October 4th. The stock was sold at an average price of $42.92, for a total value of $8,628,722.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Michael F. Mahoney also recently made the following trade(s):
- On Tuesday, September 7th, Michael F. Mahoney sold 201,041 shares of Boston Scientific stock. The shares were sold at an average price of $44.57, for a total transaction of $8,960,397.37.
NYSE BSX traded up $0.03 on Tuesday, reaching $42.44. The company’s stock had a trading volume of 5,321,014 shares, compared to its average volume of 7,752,225. Boston Scientific Co. has a 52 week low of $32.99 and a 52 week high of $46.28. The company has a current ratio of 1.66, a quick ratio of 1.31 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average price of $44.56 and a 200 day moving average price of $42.83. The firm has a market cap of $60.43 billion, a PE ratio of 128.52, a price-to-earnings-growth ratio of 2.93 and a beta of 0.88.
Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Monday, July 26th. The medical equipment provider reported $0.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.03. Boston Scientific had a net margin of 4.56% and a return on equity of 12.67%. The firm had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $2.94 billion. During the same quarter in the prior year, the company posted $0.08 earnings per share. The business’s revenue was up 53.6% on a year-over-year basis. Analysts anticipate that Boston Scientific Co. will post 1.61 earnings per share for the current fiscal year.
Gold’s on pace to smash its records. This miner’s potential is jaw dropping.
A number of institutional investors have recently bought and sold…
